基于生物信息学分析急性心肌梗死合并慢性阻塞性肺疾病的关键基因和潜在药物

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (1278 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To provide a new bioinformatics basis for the diagnosis and treatment of the disease, we analyzed the key genes and potential drugs of acute myocardial infarction (AMI) complicated with chronic obstructive pulmonary disease (COPD) based on bioinformatics. Methods Three data sets containing AMI and COPD microarray information were downloaded from the GEO database and differentially expressed genes (DEG) were screened. GO function annotation, KEGG pathway enrichment analysis, and Metascape enrichment analysis were performed on the differentially expressed genes shared by the two diseases. Then a protein protein interaction (PPI) network was constructed to identify key genes involved in the occurrence and development of diseases. Finally, the drug-drug gene interaction database was used to find potential therapeutic drugs. Results After integrating the three data sets of AMI and COPD, 61 DEGs were obtained. The results of GO function annotation showed that they were mainly involved in inflammation, carbohydrate and glucocorticoid receptor binding. Mostly located in the outer membrane of organelles and the inner cavity of particles. KEGG and Metascape enrich the pathways such as immune, inflammation, and apoptosis. Eight key genes identified by the PPI network, a total of 74 potentially related therapeutic drugs were screened. Tuberculin, tomalizumab, resveratrol caproic acid, tasquinide, and pannimod were highly associated with diseases. Conclusion The identified genes and pathways may be potential therapeutic targets for AMI combined with COPD, and provide a new basis for the molecular mechanism of the disease.

Key words： Acute myocardial infarction Chronic obstructive pulmonary disease Bioinformatics

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Chenyang LI Shuo CHAO Xiaoying ZHONG Guoqiang

Cite this article:

JIANG Chenyang LI Shuo CHAO Xiaoying ZHONG Guoqiang. Analysis of key genes and potential drugs in acute myocardial infarction combined with chronic obstructive pulmonary disease based on bioinformatics[J]. 中国医药导报, 2021, 18(28): 13-17.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I28/13

[1] Ratcovich H，Josiassen J，Helgestad OKL，et al. Incidence，Predictors，and Outcome of In-Hospital Bleeding in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction [J]. Am J Cardiol，2021，144（3）：13-19.
[2] Benjamin EJ，Blaha MJ，Chiuve SE，et al. Heart Disease and Stroke Statistics-2017 Update：A Report From the American Heart Association [J]. Circulation，2017，135（10）：e146-e603.
[3] Singh D，Long G，Can?觭ado JED，et al. Small airway disease in chronic obstructive pulmonary disease：insights and implications for the clinician [J]. Curr Opin Pulm Med，2020，26（2）：121-125.
[4] Obi J，Mehari A，Gillum R. Mortality Related to Chronic Obstructive Pulmonary Disease and Co-morbidities in the United States，A Multiple Causes of Death Analysis [J]. COPD，2018，15（2）：200-205.
[5] Rothnie KJ，Smeeth L，Herrett E，et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease [J]. Heart，2015，101（14）：1103-1110.
[6] Sin DD，Anthonisen NR，Soriano JB，et al. Mortality in COPD：Role of comorbidities [J]. Eur Respir J，2006，28（6）：1245-1257.
[7] Su TH，Chang SH，Chen PC，et al. Temporal Trends in Treatment and Outcomes of Acute Myocardial Infarction in Patients With Chronic Obstructive Pulmonary Disease：A Nationwide Population-Based Observational Study [J]. J Am Heart Assoc，2017，6（3）：624-631.
[8] Rothnie KJ，Yan R，Smeeth L，et al. Risk of myocardial infarction （MI） and death following MI in people with chronic obstructive pulmonary disease （COPD）：a systematic review and meta-analysis [J]. BMJ Open，2015，5（9）：78-81.
[9] Muse ED，Kramer ER，Wang H，et al. A Whole Blood Molecular Signature for Acute Myocardial Infarction [J]. Sci Rep，2017，7（1）：122-126.
[10] Heinbockel L，Marwitz S，Schromm AB，et al. Identification of novel target genes in human lung tissue involved in chronic obstructive pulmonary disease [J]. Int J Chron Obstruct Pulmon Dis，2018，13（22）：55-59.
[11] Ezzie ME，Crawford M，Cho JH，et al. Gene expression networks in COPD：microRNA and mRNA regulation [J]. Thorax，2012，67（2）：122-131.
[12] Lin CF，Su CJ，Liu JH，et al. Potential Effects of CXCL9 and CCL20 on Cardiac Fibrosis in Patients with Myocardial Infarction and Isoproterenol-Treated Rats [J]. J Clin Med，2019，8（5）：43-47.
[13] R?觟hrl J，Yang D，Oppenheim JJ，et al. Specific binding and chemotactic activity of mBD4 and its functional orthologue hBD2 to CCR6-expressing cells [J]. J Biol Chem，2010，285（10）：7028-7034.
[14] Safa A，Rashidinejad HR，Khalili M，et al. Higher circulating levels of chemokines CXCL10，CCL20 and CCL22 in patients with ischemic heart disease [J]. Cytokine，2016， 83（1）：47-57.
[15] Demedts IK，Bracke KR，Vanpottelberge G，et al. Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease [J]. Am J Respir Crit Care Med，2007， 175（10）：121-126.
[16] Iwata A，Morgan-stevenson V，Schwartz B，et al. Extracellular BCL2 proteins are danger-associated molecular patterns that reduce tissue damage in murine models of ischemia-reperfusion injury [J]. PLoS One，2010，5（2）：e9103-e9106.
[17] Yang D，Yan Y，Hu F，et al. CYP1B1，VEGFA，BCL2，and CDKN1A affect the Development of Chronic Obstructive Pulmonary Disease [J]. Int J Chron Obstruct Pulmon Dis，2020，15（1）：67-75.
[18] Dejesus NM，Wang L，Lai J，et al. Antiarrhythmic effects of interleukin 1 inhibition after myocardial infarction [J]. Heart rhythm，2017，14（5）：727-736.
[19] Li HL，Zhuo ML，Wang D，et al. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction [J]. Circulation，2007，115（14）：1885-1894.
[20] Momtazi G，Lambrecht BN，Naranjo JR，et al. Regulators of A20 （TNFAIP3）：new drug-able targets in inflammation [J]. Am J Physiol Lung Cell Mol Physiol，2019，316（3）：L456-L469.
[21] Sheng X，Fan T，Jin X. Identification of Key Genes Involved in Acute Myocardial Infarction by Comparative Transcriptome Analysis [J]. Biomed Res Int，2020，2020（14）：70-81.
[22] Heger LA，Hortmann M，Albrecht M，et al. Inflammation in acute coronary syndrome：Expression of TLR2 mRNA is increased in platelets of patients with ACS [J]. PLoS One，2019，14（10）：e122-e124.
[23] Marinkovi■ G，Koenis DS，Decamp L，et al. S100A9 Links Inflammation and Repair in Myocardial Infarction [J]. Circ Res，2020，127（5）：664-676.
[24] Railwah C，Lora A，Zahid K，et al. Cigarette smoke induction of S100A9 contributes to chronic obstructive pulmonary disease [J]. Am J Physiol Lung Cell Mol Physiol，2020，131（1）：234-241.
[25] Zhao Y，Tian B，Sun H，et al. Pharmacoproteomics reveal novel protective activity of bromodomain containing 4 inhibitors on vascular homeostasis in TLR3-mediated airway remodeling [J]. J Proteomics，2019，205（10）：34-38.